You are here: Industry Insights > Lilly

News List

Lilly, Incyte reveal earlier-than-expected refiling for baricitinib fiercebiotech
August 31, 2017
New application will include new safety and efficacy data.
Lilly to File Baricitinib Resubmission to U.S. FDA before end of January 2018 americanpharmaceuticalreview
August 31, 2017
Eli Lilly and Incyte announced that Lilly will resubmit the New Drug Application (NDA) for baricitinib before the end of January 2018. Baricitinib is a once-daily oral investigational medication for the treatment of patients with moderate-to-severe rheuma
Collaboration between Lilly and CRUK progresses to clinical trials pharmafile
August 24, 2017
Cancer Research UK has announced that its collaboration with Eli Lilly for the treatment of advanced solid tumours will progress to the clinic, with trials taking place across four centres in the UK.
Novo diabetes drug outperforms Lilly rival at Phase 3 pharmafile
August 18, 2017
Novo Nordisk has revealed that its diabetes drug semaglutide managed to outperform Eli Lilly’s own treatment dulaglutide (Trulicity) in controlling glucose levels and promoting weight loss in patients with the ...
Lilly’s novel migraine drug hits PhIII targets pharmatimes
August 08, 2017
Eli Lilly’s investigational, oral, first-in-class molecule lasmiditan has hit key targets a late-stage trial assessing its safety and efficacy as a treatment for acute migraine, raising hopes for a new approach to managing the condition
Boehringer Ingelheim and Lilly to support new American College of Cardiology program to highlight th lilly
August 01, 2017
Boehringer Ingelheim and Eli Lilly and Company announced that the companies will support an American College of Cardiology (ACC) program focused on driving quality improvement in cardiology and...
RA pill setback spoils Lilly’s growth story pharmaphorum
July 27, 2017
Eli Lilly has posted a strong 8% increase in sales for the second quarter, led by growth of new products such as Trulicity, Taltz and Jardiance.
Lilly and Nektar partner to develop new immunological therapy NKTR-358 pharmaceutical-technology
July 27, 2017
Eli Lilly and Company has entered a strategic collaboration to co-develop Nektar Therapeutics’ new immunological therapy NKTR-358.
Lilly and Incyte Provide Update on Baricitinib lilly
July 26, 2017
Eli Lilly and Company (NYSE: LLY) and Incyte Corporation (NASDAQ: INCY) announced that a resubmission to the U.S. Food and Drug Administration (FDA) for the New Drug Application (NDA) for baricitinib will be delayed beyond 2017.
Lilly Reports Second-Quarter Results lilly
July 26, 2017
Eli Lilly and Company (NYSE: LLY) today announced financial results for the second quarter of 2017.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 25 26 Next page